{"id":58668,"date":"2024-02-28T05:22:29","date_gmt":"2024-02-28T05:22:29","guid":{"rendered":"https:\/\/medsname.com\/pantocid-injection\/"},"modified":"2026-05-01T10:49:14","modified_gmt":"2026-05-01T10:49:14","slug":"pantocid-injection","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/pantocid-injection\/","title":{"rendered":"Pantocid Injectabil"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Pantocid Injection?<\/h3>\n

Pantocid Injectabil<\/strong> este pantoprazole sodium 40 mg per vial<\/strong> for intravenous use, made by Sun Pharma from a WHO-GMP certified manufacturing facility. This is the parenteral form of pantoprazole used in hospital when a patient cannot take oral PPI<\/strong> — nil-by-mouth, post-operative, intubated, or with active upper-GI bleeding. Doza standard:<\/strong> 40 mg IV once daily reconstituted in 0.9% saline, infused over 15 minutes. For active non-variceal upper-GI bleed<\/strong> with a high-risk endoscopic lesion (Forrest Ia\/Ib\/IIa\/IIb), the protocol is an 80 mg IV bolus followed by an 8 mg\/h continuous infusion for 72 hours. Switch to oral pantoprazole<\/strong> (e.g. Pantodac 40 mg) as soon as the patient can swallow safely. Continued IV PPI beyond 3–5 days adds nothing pharmacologically.<\/p>\n<\/div>\n

\nCe beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate ale clien\u021bilor<\/a>\n<\/div>\n

\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n

De ce s\u0103 comanzi de la MedsBase<\/h3>\n

Medicamentele noastre generice sunt procurate de la produc\u0103tori certifica\u021bi WHO-GMP \u0219i expediate la nivel mondial \u00een ambalaje discrete \u0219i simple \u2014 f\u0103r\u0103 denumirea medicamentului pe exteriorul coletului. Pl\u0103\u021bile cu cardul sunt procesate printr-un procesor reglementat (descrierile de pe extrasul de cont includ un procesor de pl\u0103\u021bi cu card reglementat \u2014 niciodat\u0103 \u201cMedsBase\u201d sau numele vreunui medicament). Accept\u0103m \u0219i criptomonede \u0219i transferuri bancare SEPA. Fiecare comand\u0103 este sus\u021binut\u0103 de Politica noastr\u0103 de Asigurare pentru Relivrare.<\/p>\n

Hospital-use medication.<\/strong> Pantocid Injection is a parenteral medication intended for inpatient or supervised clinical use. It is supplied as a sterile lyophilised powder vial that must be reconstituted with 0.9% sodium chloride and administered intravenously by a qualified healthcare professional. Self-administration of this product is not appropriate. If you can take an oral PPI, oral pantoprazole (Pantodac, Pan, Pentab, Walapan-40) or any other oral PPI gives equivalent acid suppression at a fraction of the cost.<\/div>\n

What Pantocid Injection Is<\/h2>\n

Pantocid Injection is the Sun Pharma brand of intravenous pantoprazole sodium<\/strong>. Each vial contains pantoprazole sodium equivalent to 40 mg of pantoprazole base, supplied as a sterile lyophilised powder for reconstitution. It is the parenteral form of the same molecule available orally as Pantodac, Pan, Pentab, Penlip, and Walapan-40.<\/p>\n

How Pantocid Injection Works<\/h2>\n

Pantoprazole is a benzimidazole proton-pump inhibitor. After IV administration, the drug is concentrated in the acidic secretory canaliculi of the stomach’s parietal cells. There it is protonated to the active sulphenamide form, which forms a covalent disulphide bond with cysteine residues on the H+<\/sup>\/K+<\/sup>-ATPase pump. This irreversibly blocks acid secretion until new pumps are synthesised, giving 24–72 hours of pharmacodynamic effect from each dose despite the drug’s short ~1-hour plasma half-life. Continuous infusion is used for active GI bleeding because it maintains an elevated intragastric pH at > 6 — the threshold above which platelet aggregation is preserved and clot stability is improved.<\/p>\n

Indications — When IV Pantoprazole Is Used<\/h2>\n

1. Active upper-GI bleeding from a peptic ulcer (post-endoscopy)<\/h3>\n

The largest evidence base. After endoscopic haemostasis of a high-risk lesion (active arterial bleeding Forrest Ia, oozing Ib, non-bleeding visible vessel IIa, or adherent clot IIb), a 72-hour IV PPI infusion at 80 mg bolus + 8 mg\/h reduces rebleeding, surgery, and 30-day mortality. Patients with low-risk lesions (Forrest IIc\/III) do not need IV therapy and can go straight to oral high-dose pantoprazole.<\/p>\n

2. Patients NPO (nil by mouth) needing acid suppression<\/h3>\n

Post-operative ileus, mechanical ventilation, severe pancreatitis, persistent vomiting, or dysphagia. Once enteral nutrition resumes, switch to oral pantoprazole.<\/p>\n

3. ICU stress-ulcer prophylaxis<\/h3>\n

For mechanically ventilated patients > 48 hours, those with coagulopathy, or those on vasopressors. Note: prolonged ICU PPI use is associated with increased C. difficile<\/em> infection and ventilator-associated pneumonia — review the indication daily and stop when no longer needed.<\/p>\n

4. Zollinger-Ellison syndrome — bridging<\/h3>\n

For patients with acid hypersecretory states who cannot take oral PPI temporarily.<\/p>\n

Dozare \u0219i administrare<\/h2>\n\n\n\n\n\n\n\n\n\n
Indica\u021bie<\/th>\nDoza<\/th>\nNote<\/th>\n<\/tr>\n<\/thead>\n
Doza standard pentru adul\u021bi<\/td>\n40 mg IV once daily<\/td>\nReconstitute with 10 mL 0.9% sodium chloride; may further dilute in 100 mL 0.9% NaCl; infuse over 15 minutes<\/td>\n<\/tr>\n
Upper-GI bleed (high-risk lesion, post-endoscopy)<\/td>\n80 mg IV bolus, then 8 mg\/h continuous infusion<\/td>\n72 hours, then step down to oral 40 mg twice daily for 14 days<\/td>\n<\/tr>\n
Severe Zollinger-Ellison<\/td>\n80 mg IV every 8–12 hours (specialist-led)<\/td>\n0.9% NaCl reconstitution; specialist supervision<\/td>\n<\/tr>\n
Insuficien\u021b\u0103 hepatic\u0103<\/td>\nMaximum 40 mg\/day<\/td>\nMonitor LFTs<\/td>\n<\/tr>\n
Insuficien\u021b\u0103 renal\u0103<\/td>\nNo dose adjustment needed<\/td>\nRegim standard<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Compatibility:<\/strong> Reconstitute only with 0.9% sodium chloride. Do not mix with other IV medications in the same line. The reconstituted solution is stable for 12 hours at room temperature; discard any unused portion.<\/p>\n

Switch to oral PPI<\/strong> as soon as the patient can swallow safely. Continued IV PPI beyond 3–5 days has no pharmacological advantage over oral therapy and adds substantially to cost and infection risk.<\/p>\n

Efecte Secundare<\/h2>\n

Frecvente (1\u201310%):<\/strong> headache, diarrhoea, nausea, abdominal pain, injection-site reactions (pain, thrombophlebitis at the cannula site).<\/p>\n

Pu\u021bin frecvente, dar importante:<\/strong> hypersensitivity (rash, angioedema; very rarely anaphylaxis), acute interstitial nephritis, hepatotoxicity (rare), severe hypomagnesaemia (with prolonged use), C. difficile<\/em> infection (especially in hospitalised patients), and ventilator-associated pneumonia.<\/p>\n

Contraindica\u021bii<\/h2>\n